Arbutus Biopharma Cp (ABUS) Stock Price, Quote & News

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the poten...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 469 0914

Website: www.arbutusbio.com

Address:

701 Veterans Circle, Warminster, United States

Kruhl Oct. 25 at 6:28 PM

$ABUS Covid Vaccine helps fight cancer.

0 · Reply

Joe_Mama Oct. 25 at 4:17 PM

$ABUS Circle says we’re going up the right side next. Time will tell…

0 · Reply

DocPharm Oct. 24 at 11:14 PM

$ABUS AB-101 how to think of it… Akin to an oral Keytruda; but more controllable targeted PK = lower doses and less side effects for patients & the payers; oral much more favored than injectable; Oh & novel MoA, not only does it block the axis, it causes internalization and degradation of the complex. Applications for exhausted immune cells in virologic diseases and to ramp up tumor clearance in oncology Intrinsic value went up when they got selected for a presentation/poster with distinction. That will be at AASLD. Many more applications beyond hep B for that compound and its variants in oncology.

3 · Reply

BEATOFtheMARKET Oct. 24 at 9:46 PM

$ABUS $ABVX $ACAD $ACDC $ACEL 10/10 TO 10/24 LIST Results 🔥 Cycle Trading Signal plugged into AI 🔥

0 · Reply

JB6791 Oct. 24 at 8:13 PM

$ABUS

0 · Reply

Jacagorg09 Oct. 24 at 4:09 PM

$ABUS

0 · Reply

SpaceCityKid Oct. 24 at 3:36 PM

$ABUS NOV 5 Calls seeing action. 1002 contracts

0 · Reply

punktdot Oct. 24 at 3:32 PM

$ABUS massive bull flag forming, this is ripe for a rip

0 · Reply

Heavey Oct. 24 at 3:16 PM

$ABUS boing

1 · Reply

DocPharm Oct. 24 at 2:14 PM

$ABUS AASLD 2 weeks - be ready friends

0 · Reply

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Aug 6, 2025, 7:30 AM EDT - 2 months ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 25, 2025, 7:30 AM EDT - 4 months ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

May 14, 2025, 7:30 AM EDT - 5 months ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 2:01 AM EDT - 6 months ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Apr 23, 2025, 2:01 AM EDT - 6 months ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Mar 27, 2025, 7:56 AM EDT - 7 months ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:30 AM EDT - 7 months ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 3, 2025, 9:15 AM EST - 8 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Feb 25, 2025, 7:00 AM EST - 8 months ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Jan 30, 2025, 3:40 PM EST - 9 months ago

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

BUR CDZI

Jan 13, 2025, 7:30 AM EST - 10 months ago

Arbutus Provides 2025 Corporate and Financial Update

Jan 7, 2025, 7:56 AM EST - 10 months ago

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Dec 3, 2024, 8:00 AM EST - 11 months ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Nov 26, 2024, 7:30 AM EST - 11 months ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 15, 2024, 11:02 AM EST - 1 year ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference

Nov 6, 2024, 2:52 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Aug 1, 2024, 2:00 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 5, 2024, 5:29 AM EDT - 1 year ago

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 3, 2024, 9:50 AM EDT - 1 year ago

Arbutus Distributors Ltd. News Release

May 29, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Jefferies Global Healthcare Conference

May 22, 2024, 2:00 AM EDT - 1 year ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 17, 2024, 9:00 AM EDT - 1 year ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 2, 2024, 1:15 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:25 AM EDT - 1 year ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Apr 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 4, 2024, 8:30 AM EDT - 1 year ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Feb 29, 2024, 1:05 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:30 AM EST - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 15, 2024, 7:30 AM EST - 1 year ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Jan 8, 2024, 7:30 AM EST - 1 year ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Nov 9, 2023, 4:01 PM EST - 2 years ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 7, 2023, 11:06 AM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:30 AM EST - 2 years ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:15 AM EST - 2 years ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 18, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Oct 11, 2023, 8:05 AM EDT - 2 years ago

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Sep 11, 2023, 4:15 PM EDT - 2 years ago

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Jul 20, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

Kruhl Oct. 25 at 6:28 PM

$ABUS Covid Vaccine helps fight cancer.

0 · Reply

Joe_Mama Oct. 25 at 4:17 PM

$ABUS Circle says we’re going up the right side next. Time will tell…

0 · Reply

DocPharm Oct. 24 at 11:14 PM

3 · Reply

BEATOFtheMARKET Oct. 24 at 9:46 PM

$ABUS $ABVX $ACAD $ACDC $ACEL 10/10 TO 10/24 LIST Results 🔥 Cycle Trading Signal plugged into AI 🔥

0 · Reply

JB6791 Oct. 24 at 8:13 PM

$ABUS

0 · Reply

Jacagorg09 Oct. 24 at 4:09 PM

$ABUS

0 · Reply

SpaceCityKid Oct. 24 at 3:36 PM

$ABUS NOV 5 Calls seeing action. 1002 contracts

0 · Reply

punktdot Oct. 24 at 3:32 PM

$ABUS massive bull flag forming, this is ripe for a rip

0 · Reply

Heavey Oct. 24 at 3:16 PM

$ABUS boing

1 · Reply

DocPharm Oct. 24 at 2:14 PM

$ABUS AASLD 2 weeks - be ready friends

0 · Reply

BRTO Oct. 24 at 1:24 PM

$ABUS I’m considering the investor conf. Anyone else?

2 · Reply

LiquidThetaLEAPS Oct. 24 at 7:38 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABUS Current Share Price: $4.39 Contracts: $ABUS January 15, 2027 $4 Calls Scale in: $1.91- $2.34 Scale out: $2.97-$3.83 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Alfalcon Oct. 23 at 11:52 PM

$ABUS added

0 · Reply

Grtgooglymoogly Oct. 23 at 8:15 PM

$ABUS Chances that Ceo Lindsay will actually go on some kind of camera and talk about Arbutus sometime? I mean, I know she can talk. I've seen a couple old videos......must be the quiet period (that lasts all year)...

2 · Reply

Grtgooglymoogly Oct. 23 at 7:59 PM

$ABUS Chances they'll have a quarterly report webcast? 😁........0.0%

0 · Reply

anthonydabbraccio Oct. 23 at 6:50 PM

$ABUS I put in an order for 1000 shares at 4.36 early this morning, I've watched it sit at 4.35 4.36 and my order not filled. It's still currently 4.35

1 · Reply

BillionerOfKing Oct. 23 at 4:01 PM

$ABUS Current Stock Price: $4.41 Contracts to trade: $5 ABUS Nov 21 2025 Call Entry: $0.10 Exit: $0.17 ROI: 74% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

LiquidThetaLEAPS Oct. 23 at 10:22 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ABUS Current Share Price: $4.43 Contracts: $ABUS January 15, 2027 $4 Calls Scale in: $1.94- $2.37 Scale out: $3.01-$3.87 Can Easily Capture: 60% ROI Blended DTE: 450 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

DDRPOWER Oct. 23 at 1:05 AM

$ABUS Moderna and Biontech both went public 11 months and 2 months respectively prior to covid pandemic. Crazy facts. 😵‍💫

3 · Reply

ldaniels19 Oct. 22 at 11:25 PM

$ABUS I added to my position today. This tortoise will eventually beat the hare.

0 · Reply

Thepatientone Oct. 22 at 8:35 PM

$ABUS - I assume we found something and PFE/BNTX is asking for 2 weeks to respond.

1 · Reply

DocPharm Oct. 22 at 8:28 PM

$MRNA down she blows May have to pay a big chunk to $ABUS / $ROIV / Genevant soon, too

2 · Reply

Market Cap	592.57M
Revenue (ttm)	18.14M
Net Income (ttm)	-72.85M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	649,900
Avg Vol	936,122
Day's Range	N/A - N/A
Shares Out	188.72M
Stochastic %K	2%
Beta	1.98
Analysts	Strong Sell
Price Target	$4.50